Is it the the renin-angiotensin-aldosterone blockade a comprehensive tool for the management of cardiovascular risk?

Journal of Hypertension

Volumn 22, Issue 3, 2004, Pages 463-465

  Borghi, Claudio ^a,c   Grassi, Guido ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; LOSARTAN; RAMIPRIL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; EDITORIAL; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

EID: 1642406237     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200403000-00006     Document Type: Editorial

References (11)

1. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13:3S-10S.
2. Borghi C, Dormi A, Ambrosioni E, Gaddi A. Relative role of systolic, diastolic and pulse pressure as risk factors for cardiovascular events in the Brisighella Heart Study. J Hypertens 2002; 20:1737-1742.
3. Multiple Risk Factors Intervention Trial Research Group. Multiple Risk Factors Intervention Trial: risk factors changes and mortality results. JAMA 1982; 248:1465-1477.
4. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Increase in blood glucose concentration during antihypertensive treatment as a predictor of myocardial infarction: population based cohort study. BMJ 2003; 326:681-686.
5. Niklason A, Hedner T, Niskanen L, Lanke J for the CAPPP Study Group. Development of diabetes is retarded by ACE-inhibition in hypertensive patients - a subanalysis of the Captopril Prevention Project. J Hypertens 2004; 22:645-652.
6. Lindholm LH, Ibsen H, Borch-Johnsen K, Olsen MH, Wachtell K, Dahlof B, et al. Risk of new onset diabetes in the Losartan Intervention for Endpoint reduction in hypertension study. J Hypertens 2002; 20: 1879-1886.
7. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353:611-616.
8. HOPE Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355:253-259.
9. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47:1643-1649.
10. Pollare, LithellH, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321:868-873.
11. Follli F, Kahn CR, Hansen H, Bouchie JL, Feener EP. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997; 100:2158-2169.